A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisHoward Trachtman, Flavio Vincenti, Fernando C. Fervenza et al.|Kidney International|2011Cited by 258
Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney TransplantsSindhu Chandran, Flavio Vincenti, Erica Tavares et al.|American Journal of Transplantation|2017Cited by 219
The kSORT Assay to Detect Renal Transplant Patients at High Risk for Acute Rejection: Results of the Multicenter AART StudySilke Roedder, Minnie Sarwal, Tara K. Sigdel et al.|PLoS Medicine|2014Cited by 181
Outcomes at 7 years post‐transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in<scp>BENEFIT</scp>and<scp>BENEFIT</scp>‐<scp>EXT</scp>Sander Florman, Christian P. Larsen, Flavio Vincenti et al.|Clinical Transplantation|2018Cited by 9